TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed with axial spondyloarthritis (axSpA) (either ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA)), fulfilling the Assessment of Spondyloarthritis International Society (ASAS) classification, aged at least 18 years~* Prescription of Humira® (adalimumab) for treating axSpA according to the local product label~* Eligibility for active physiotherapy according to the rheumatologist and physiotherapist~* Participants must have signed written informed consent before starting any study related assessments or procedures.~Exclusion Criteria:~* Participants with total spinal ankylosis based on the investigators' assessments of available radiographs~* Participants who are not eligible for active supervised training or active physiotherapy at the discretion of the rheumatologist and/or the physiotherapist~* Participants with poorly controlled medical condition(s), which in the opinion of the investigator, would put the participant at risk by participation in the protocol~* Any prior treatment with a biologic disease-modifying antirheumatic drugs (DMARD) is prohibited.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Active Supervised Training (AST) (Type: None): Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive active supervised and standardized training (AST).
- Standard of Care (SOC) Physiotherapy (Type: None): Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive standard of care physiotherapy, according to the physiotherapist discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sexual Functioning After Primary Treatment of Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women with any stage of invasive epithelial ovarian cancer who have completed frontline therapy within the past 6 months~* Women must have no clinical evidence of disease~* At least 18 years of age~* English speaking~* Able to participate in the informed consent process~* Women who present to Sexual Health Clinic for the first time and meet all other eligibility criteria are eligible. Their FSFI scores will be used to determine the primary endpoint of prevalence of sexual dysfunction. If they score over 26 on the FSFI, they may still elect to be followed at the SHC.~Exclusion Criteria:~* Active secondary cancer requiring cytotoxic chemotherapy at the time enrollment~* Evidence of recurrent/persistent disease by elevated CA125, findings on imaging (CT, PET scan etc) or physical examination~* Women with borderline (low malignant potential) ovarian cancers~* Women who are already in active evaluation and/or follow-up at the Sexual Health Clinic~* Women with a history of prior whole pelvic radiation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): FSFI score \<= 26
- 2 (Type: None): FSFI score \>26

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Definite or probable ischemic stroke~* CT angiographic (CTA) evidence of intracranial vascular occlusion (internal carotid, middle cerebral - M1 or M2 divisions, anterior cerebral, posterior cerebral, or basilar artery) within 3.5 hours of symptom onset~* Able to receive assigned treatment within 4.5 hours of symptom onset~* Written informed consent from patient or surrogate, if unable to provide consent~Exclusion Criteria:~* CT evidence of early infarction in \>1/3 of middle cerebral artery distribution~* Blood pressure \> 185/110 mmHg refractory to anti-hypertensive therapy~* History of intracranial hemorrhage~* History of ischemic stroke within past 3 months~* History of major surgical procedure within past 14 days~* Gastrointestinal or genitourinary bleeding within past 14 days~* Glucose \<50 or \>400mg/dL~* Platelet count \<100,000~* International normalized ratio (INR) ≥ 1.7~* Known history of bleeding diathesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous Thrombolysis (Type: ACTIVE_COMPARATOR): 0.9mg/kg intravenous rt-PA (max dose 90mg) - 10% administered as a bolus over 1 minute and the remainder infused over 60 minutes.
- Endovascular Arterial Reperfusion (Type: ACTIVE_COMPARATOR): Therapeutic options will include mechanical thrombectomy/clot disruption (Penumbra aspiration system, Solitaire device, and/or Reflex catheter) and/or intracranial stent deployment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Open Label Trial to Assess the Safety and Efficacy of the OptiVein IV Catheter in an Oncologic Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients on an ongoing chemotherapy program thru peripheral veins delivery~2. Has difficult to access veins (class II or III) OR has experienced an unsuccessful IV start during his/her previous visit to the hospital~3. Requires peripheral IV therapy (catheter)~4. Has an insertion site in the forearm or hand free of deformities, phlebitis, infiltration, dermatitis, burns, lesions or tattoos~5. Demonstrates cooperation with a catheter insertion and the study protocol~6. Patients 18 years of age or greater~Exclusion Criteria:~1. Patients receiving pre-warming of the insertion site~2. Is anesthetized~3. Has a life expectancy of less than one month~4. Transferred from the operating room less than 8 hours post-anasthesia~5. Any patient the research staff deem unobservable~6. The study IV site needs to be immobilized with a splint or other devices~7. Will require a power injection for a radiologic procedure during participation in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OptiVein IV catheter (Type: EXPERIMENTAL): Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
- Vasofix Certo IV catheter (Type: ACTIVE_COMPARATOR): Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Alcohol on ABCA1 Expression and Lipid Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy participants~* Aged 18-65 years~* Free of overt coronary disease~* BMI \< 35~* Fasting plasma glucose \<6.1 mmol~* Unmedicated~* No major illness~Exclusion Criteria:~* Unable to give informed consent~* Smokers~* Participants with alcoholism

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Probiotic (L.Reuteri) Survival in Presence of Prebiotic Galacto-oligosaccharides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Child is between 24 months to 36 months of age.~2. Singleton, full-term gestational birth (≥ 37 completed weeks of gestation), with a birth weight of ≥ 2.5 kg and ≤ 4.5 kg.~3. Healthy status based on medical history and physical examination~4. Weight- for-age and height-for-age within normal range on local childhood growth chart.~5. Written informed consent are obtained from both parents/legally authorized representative (LAR).~6. Parents/legally authorized representative must be able to provide evidence of the parental authority and identity.~7. Parents /legally authorized representative are of legal age of consent and must understand the informed consent and other study documents.~8. Parents/legally authorized representative are willing and able to fulfill the requirements of the study protocol.~Exclusion Criteria:~1. Known or suspected cows' milk protein intolerance / allergy, or lactose intolerance, or significant food allergies that impact a normal diet.~2. Prior to study participation, child has shown limited or no interest in drinking toddler milk.~3. Chronic infectious, gastrointestinal, metabolic, or genetic disease, including any disease/condition that impacts feeding or growth.~4. Use of systemic antibiotics or anti-mycotic medication in the 4 weeks preceding enrollment.~5. Child is currently consuming or has consumed any formulas or taking any supplement containing L. reuteri in the past 3 months.~6. Child is currently consuming or has consumed any formulas or taking any supplement containing GOS within the past 48 hrs prior to product in take, and who are not willing accept a temporary cessation of the consumption during the study period.~7. Child is currently participating in another investigational clinical trial.~8. Family or hierarchical relationships with the CIL team.

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 36 Months
- Healthy Volunteers: t

Study Arms:
- TEST1 (Type: EXPERIMENTAL): None
- TEST2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Sars-Cov2 Neuroinvasiveness - COVID19

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* COVID-19 patients requiring an external ventricular drain, a decompressive craniectomy or an intracranial hematoma surgery~Exclusion Criteria:~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neurological biological samples (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of CNAP During Anesthesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>18~* ASA II, III or IV~* weight between 40 and 180 kg; BMI \< 35~* surgical procedure performed in supine position~* normal Allen's test and hand Doppler examination.~Exclusion Criteria:~* cardiac arrhythmias,~* history of vascular surgery or vascular implant in the upper limb

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes~* Elective cardiac surgery~Exclusion Criteria:~* Emergency procedures~* Preop myocardial infarction~* Preop cardiac failure~* Preop renal replacement therapy

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Sevoflurane (Type: EXPERIMENTAL): Volatile anesthesia for elective cardiac surgery
- Propofol (Type: ACTIVE_COMPARATOR): Total intravenous anesthesia for elective cardiac surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Brain Perfusion Assessment in the Acute Phase of Migraine Aura

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age between greater than or equal to 18~* Able to undergo MRI during migraine aura~Exclusion Criteria:~* Pregnant females~* Contraindications towards MRI scanning~* History of epilepsy, psychiatric disease, or any other neurologic disease (brain tumors, stroke..).~* Presence of abnormalities on the MRI that could explain the neurological deficit.~* Adults under guardianship or trusteeship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Healthy Participants (Part A and Part B)~* Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination (PE), electrocardiograms (ECGs), and clinical laboratory determinations~* Males and Females, ages 18, or local age of majority, to 50 years, inclusive at screening~* Body mass index (BMI):18.0 to 30.0 kg/m2, weight: ≥ 50 kg at screening~* Must be fully vaccinated against SARS-CoV-2~Participants with Sjögren's Syndrome (Part C)~* Sjögren's syndrome in the absence of another immune-mediated disease or rheumatologic condition based on the 2016 American College of Rheumatology-European League Against Rheumatism (EULAR) Classification Criteria for primary Sjögren's syndrome (pSS). Historical diagnosis as pSS documented in medical records, using the 2016 ACR/EULAR criteria, is also acceptable~* Seropositive for anti-Sjögren's syndrome antigen A antibody (anti-SSA). Previous anti-SSA are also acceptable, and results should be documented in the Case Report Form (CRF) as past medical history~* Males and females, ages 18, or local age of majority, to 75 years, inclusive at screening~* Body mass index (BMI): 18.0 to 35.0 kg/m2; weight ≥ 50 kg at screening~* Must be fully vaccinated against SARS-CoV-2 according to local regulations~Exclusion Criteria:~Healthy Participants (Part A and Part B) - Any significant acute or chronic medical illness~Healthy Participants (Part A and Part B) and Participants with Primary Sjögren's Syndrome (pSS) (Part C)~- Any major surgery within 4 weeks prior to study drug administration, or any surgery planned during the course of the study~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Part A (SAD) (Type: EXPERIMENTAL): Single Ascending Dose (SAD)
- Part A (SAD) Placebo (Type: PLACEBO_COMPARATOR): None
- Part B (MAD) (Type: EXPERIMENTAL): Multiple Ascending Dose (MAD)
- Part B (MAD) Placebo (Type: PLACEBO_COMPARATOR): None
- Part C (pSS) (Type: EXPERIMENTAL): Primary Sjögren's Syndrome (pSS)
- Part C (pSS) Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gene-by-Stress Interactions in Intervention Studies Significance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women who have been enrolled in the STRRIDE, ENHANCED, and/or REMIT studies age 18 years or greater.~* Ability and willingness to provide informed consent.~* Individuals with specific genotypes as determined from our previous work on their samples through Aim 1 of this project.~Exclusion Criteria:~* Women who are known to be pregnant, intend to become pregnant, or breast-feeding will be excluded. Women who are of child bearing potential (under age 55) will be informed that they will need to have their urine tested for pregnancy and that they should not participate in the research if they are not willing to have the Investigators provide them with information on positive pregnancy test results. Subjects will be informed that the pregnancy testing is not being performed for clinical purposes and that the testing is not a substitute for their regular medical care if they need to know whether or not they may be pregnant.~* History of Type II diabetes mellitus.~* History of prolonged QT interval.~* Participation in an investigational drug trial within the last 30 days.~* Already taking either ziprasidone or lorcaserin or any potential confounding medications, for example, other weight loss medications or psychotropic medications.~* Unwillingness to fast for at least 6 hours prior to the research study visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ziprasidone (Type: ACTIVE_COMPARATOR): Ziprasidone 60 mg tablet by mouth, once a day for one day.
- Lorcaserin (Type: ACTIVE_COMPARATOR): Lorcaserin 20 mg tablet by mouth, once a day for one day.
- Placebo Oral Tablet (Type: PLACEBO_COMPARATOR): Sugar pill (in place of ziprasidone and lorcaserin) by mouth, once a day for one day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Conventional Dose Regimen and New Dose Regimen of Pregabalin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pain score NRS ≥3 Patients complaining of neuropathic pain (except neuropathic pain due to chemotherapy)~* Adult patients aged 19 to 85 years~* Patients who pre-agreed to the study~Exclusion Criteria:~* Patients complaining of severe pain (NRS ≥ 8)~* Creatinine clearance of \<30 mL / min, the liver was more than 3 times normal~* Patients complaining of dizziness, patients with definite orthostatic hypotension~* Pregnant or lactating patients~* Patients who previously experienced side effects after administration pregabalin.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Pregabalin 75mg bid (Type: ACTIVE_COMPARATOR): The patients who were prescribed according to the conventional flexible dose regimen
- pregabalin 25mg,50mg (Type: EXPERIMENTAL): The patients who were prescribed according to the new flexible dose regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues